Skip to main content
Premium Trial:

Request an Annual Quote

Bridge Bio and Finnzymes Form PCR Venture to Sell PCR Technologies

NEW YORK (GenomeWeb News) — Finnzymes Instruments and Bridge Bioscience have created a joint venture and started a new company to sell certain PCR technologies.
Under the agreement, Bridge Bio will transfer all of the physical assets and patents in its PCR business to the new company, called BioInnovations Oy, which will be controlled by Finnzymes.
According to BridgeBio’s website, the company’s PCR portfolio includes reagents and products for electroporation, electrophoresis, and transfection.
Finnzymes, a PCR and RNA technologies company based in Esposo, Finland, has purchased a majority stake in the new company.
BioInnovations Oy will be based in Finland, but will have a US subsidiary called BioInnovations Inc., according to Bridge Bio President Bruce Turner.
Turner will take over as CEO of BioInnovations Inc., and will serve as COO of BioInnovations Oy.
Financial terms of the agreement were not released.

The Scan

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.

DNA Storage Method Taps Into Gene Editing Technology

With a dual-plasmid system informed by gene editing, researchers re-wrote DNA sequences in E. coli to store Charles Dickens prose over hundreds of generations, as they recount in Science Advances.

Researchers Model Microbiome Dynamics in Effort to Understand Chronic Human Conditions

Investigators demonstrate in PLOS Computational Biology a computational method for following microbiome dynamics in the absence of longitudinally collected samples.

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.